YC-1: Dual sGC Activator & HIF-1α Inhibitor for Cancer and Hypoxia Research

Executive Summary: YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a small molecule that activates soluble guanylyl cyclase (sGC) and inhibits hypoxia-inducible factor-1α (HIF-1α) at the post-transcriptional level, blocking HIF-1 transcriptional activity (APExBIO, Product Page). In vitro, YC-1 suppresses platelet aggregation and vascular contraction through sGC activation. In vivo, it reduces tumor size and angiogenesis by decreasing HIF-1α and its inducible genes (Zhou et al., 2026, DOI). The compound shows an IC₅₀ of 1.2 µM for hypoxia-induced HIF-1 transcriptional activity and is highly soluble in DMSO and ethanol but insoluble in water. YC-1 is supplied by APExBIO with ≥98% purity for research use only.

Biological Rationale

Hypoxia-inducible factor-1α (HIF-1α) is a master transcription factor regulating genes essential for tumor survival, angiogenesis, and adaptation to hypoxic environments (Zhou et al., 2026). HIF-1α upregulation promotes tumor growth, metastasis, and resistance to therapy. Soluble guanylyl cyclase (sGC) is an enzyme that, upon activation, increases cyclic GMP (cGMP) levels, leading to vasodilation and inhibition of platelet aggregation. Disrupting HIF-1α activity and modulating sGC/cGMP signaling are promising strategies in cancer, vascular, and hypoxia research. YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol, as provided by APExBIO, is uniquely positioned as a dual-function tool compound: it inhibits HIF-1α and activates sGC, enabling targeted interrogation of both pathways (YC-1: Dual sGC Activator & HIF-1α Inhibitor). This article extends previous reviews by integrating new in vivo benchmarks and translational perspectives.

Mechanism of Action of YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol

YC-1 operates via two primary mechanisms:

• HIF-1α Inhibition: YC-1 blocks HIF-1α protein accumulation under hypoxic conditions by inhibiting its translation and promoting proteasomal degradation. This action prevents HIF-1α from activating target genes involved in angiogenesis (e.g., VEGF), glycolysis, and cell survival (Zhou et al., 2026).
• sGC Activation: Independently of nitric oxide (NO), YC-1 binds to sGC, stimulating cGMP production. Elevated cGMP causes smooth muscle relaxation, vasodilation, and inhibition of platelet aggregation. This mechanism underlies YC-1's vascular effects (YC-1: Soluble Guanylyl Cyclase Activator & HIF-1α Inhibitor).

These dual actions make YC-1 an ideal probe for dissecting the crosstalk between hypoxia signaling and vascular biology. The compound’s effects are dose-dependent, with an IC₅₀ of 1.2 µM for HIF-1 transcriptional inhibition (APExBIO, Product Page).

Evidence & Benchmarks

• YC-1 inhibits hypoxia-induced HIF-1 transcriptional activity in vitro with an IC₅₀ of 1.2 µM (APExBIO, product page).
• In murine tumor models, YC-1 treatment results in smaller, less vascularized tumors and reduced expression of HIF-1α and VEGF (Zhou et al., 2026, DOI).
• YC-1 activates sGC and increases cGMP levels, leading to inhibition of platelet aggregation and vascular contraction in ex vivo assays (internal summary).
• Transcriptomic and proteomic studies confirm YC-1’s selective inhibition of the HIF-1α/BNIP3L axis, affecting mitophagy and oxidative stress in hypoxia (Zhou et al., 2026).
• YC-1 shows high solubility in DMSO (≥30.4 mg/mL) and ethanol (≥16.2 mg/mL), but is insoluble in water (APExBIO, specifications).

This review updates and benchmarks the molecular specificity and translational impact of YC-1 relative to earlier summaries (cf. Advanced Insights into HIF-1α Inhibition and Mitophagy, which focused on mechanistic integration but did not cover new in vivo data presented here).

Applications, Limits & Misconceptions

Applications: YC-1 is validated for:

• In vitro inhibition of hypoxia-induced gene expression in cancer and vascular cells.
• In vivo suppression of tumor angiogenesis and growth in preclinical models.
• Dissecting the roles of HIF-1α and cGMP pathways in hypoxia, apoptosis, and mitochondrial quality control research.
• Screening and benchmarking of hypoxia pathway inhibitors and sGC activators in translational workflows (Revolutionizing Hypoxia and Cancer Research—this article presents translational strategies not detailed in the present mechanistic summary).

YC-1 is intended for scientific research use only and is not approved for diagnostic or therapeutic use in humans or animals (APExBIO, product page).

Common Pitfalls or Misconceptions

• YC-1 is not a direct inhibitor of HIF-1α DNA binding; it acts mainly at the post-transcriptional and protein stability levels.
• YC-1 is not soluble in water; improper solvent use can compromise experimental results.
• The compound’s sGC activation is NO-independent; it does not require co-treatment with nitric oxide donors.
• YC-1 is not a pan-angiogenesis inhibitor; its effects are HIF-1α-dependent and may not generalize across all angiogenic pathways.
• Long-term storage of YC-1 solutions is not recommended due to potential degradation; solutions should be freshly prepared and used promptly (APExBIO, specifications).

Workflow Integration & Parameters

For optimal use, YC-1 should be dissolved in DMSO or ethanol to a working concentration ≤30.4 mg/mL or 16.2 mg/mL, respectively. Stock solutions should be aliquoted and stored at room temperature, protected from light, and used within a short time frame to preserve compound integrity. Typical in vitro assays employ concentrations in the 0.5–10 µM range, with observed IC₅₀ for HIF-1α inhibition at 1.2 µM under hypoxic conditions. In vivo dosing regimens should be determined based on pharmacokinetic and pharmacodynamic profiling. Researchers are advised to use high-purity preparations (≥98%) and validate compound identity by NMR or mass spectrometry if critical for downstream applications.

YC-1’s dual activity requires careful experimental design to distinguish sGC/cGMP effects from HIF-1α inhibition. For applications in apoptosis, mitochondrial quality control, and hypoxia signaling, YC-1 can be combined with genetic or pharmacological modulators to elucidate pathway-specific mechanisms (Harnessing Dual Pathways—this analysis focuses on workflow strategies for maximizing reproducibility and mechanistic clarity, complementing the current article's new evidence synthesis).

Conclusion & Outlook

YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol remains a gold-standard tool for interrogating the crosstalk between hypoxia signaling and vascular modulation. Its dual function as a soluble guanylyl cyclase activator and HIF-1α inhibitor enables precise dissection of pathways underlying tumor angiogenesis, apoptosis, and mitochondrial dynamics. The compound is validated across in vitro and in vivo models with well-defined solubility and purity profiles, as supplied by APExBIO. Future research directions include refining its selectivity profile, optimizing dosing strategies, and integrating YC-1 into multi-modality screens for cancer and ischemic disease models. For comprehensive product specifications and ordering, refer to the APExBIO YC-1 (B7641) product page.